



MARKET RELEASE

9 November 2017

Living Cell Technologies Limited

TRADING HALT

The securities of Living Cell Technologies Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Monday, 13 November 2017 or when the announcement is released to the market.

Security Code: LCT

George Tharian
ADVISER, LISTINGS COMPLIANCE (SYDNEY)



Living Cell Technologies Limited

ACN: 104 028 042

ASX: LCT

OTCQX: LVCLY

9 November 2017

Ms Charlotte Hope
Adviser
ASX Compliance
20 Bridge Street
Sydney NSW 2000

Email: charlotte.hope@asx.com.au

Dear Ms Hope,

Trading Halt Request

Pursuant to ASX Listing Rule 17.1, Living Cell Technologies Limited ("LCT") seeks a trading halt with immediate effect pending the NTCELL Parkinson's disease clinical trial results announcement to the ASX, expected on Friday 10 November 2017.

The proposed trading halt is expected to last until the earlier of the commencement of trading on Monday 13 November 2017 or the release of an announcement to ASX. LCT is not aware of any reason why the trading halt should not be granted.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Mark Licciardo', with a long, sweeping horizontal stroke extending to the right.

Mark Licciardo
Company Secretary